CLV
Anyone who’s interested in CLV,here is some info that basically outlines what the company does and its products available and why i believe it may well be a success
Clover currently operates in the Infant Formula & Medical Foods market and has research and development teams exploring the Sports & Nutrition Drinks and Powders Market
Clover provides vital ingredients in products sold here and abroad from companies that manufacture their products mainly in Australia and NZ but also China with a vision of going truly global this year
I find Clover in somewhat a win/win situation being able to directly benefit in Chinese uptake of Oz Infant formula products by supplying the Manufacturers here in Australian and Nz.
What Clover also benefit from is a Chinese community that trusts there products.
China’s Manufactures will then be also trusted when Clover ingredients are used.
Meaning any switch in market share of end product should have minimal effect to Clovers distribution as Clover deals with many Names on abvariety of different tins.
What I’m trying to say is that no matter who’s selling the Infant Formula,Sports Drinks or Powders ,
Clover are in a position to benefit due to being an industry leader and trusted company name.
Today Clover continue to focus on improving human health through nutrition and have become a global leader in the delivery of stable omega-3 and omega-6 products in to the infant nutrition and medical foods market with a reputation of excellence and quality.
Clover also has rock solid industry and research partners.
Products
Nu-MegaDriphorm® powders utilise CSIRO’s MicroMax technology under exclusive licence to microencapsulate nutritional oils. The patented technology allows up to a 50% oil payload with superior odour and taste masking. With a proven track record since 2001, Nu-Mega Driphorm powders are internationally recognised as the benchmark for quality and stability. Nu-Mega Driphorm powders are used in a wide range of infant formula, follow-on formula, growing up milks and food applications.
Nu-Mega Driphorm® HA
For non-dairy application Nu-Mega Driphorm® HA is recommended. Cow’s milk protein allergy affects around 2-6% of children with the highest prevalence during the first year of life. Nu-Mega Driphorm® HA is utilises a patented carbohydrate technology which meets regulatory guidelines around the world.
Nu-Mega HiDHA® tuna oils
Clover products are sourced from high quality tuna oil. Utilising the latest extraction technologies, crude oil is supplied under strict industry specifications. Through years of experience in tuna oil purification we have developed an expertise which allows further refining, delivering a highly refined tuna oil which meets infant formula and pharmaceutical standards.
Ocean Gold®
Clover products are cold pressed, super refined tuna oils. It is a non winterised product cloudy at room temperature. This natural triglyceride oil contains approximately 27% DHA and 35% total omega-3 fatty acids.
Clover have a range of oils that meet the following:
GOED Monograph standard
EU approved
Halal approved
Kosher approved
Sustainable fishing practices
Compliance with regulation (EC) 1881/2006 and 2006/141/EC on environmental contaminants minimum residue limits
Approved for use in infant and follow-on formula according to EC Directive 2006/141/EC
Compliance to EC Directive 1999/21/EC in food for special medical purpose
Clover utilises a number of microencapsulation technologies that enable nutritional oils, such as tuna, fish, algal and fungal oils, to be added to infant formula, foods and beverages.
Developed through extensive research and development, our proprietary technologies protect sensitive oils from oxidation allowing them to be incorporated into a range of end applications. In addition to their superior protection capabilities, all of our microencapsulated products reach the highest standards of purity, stability and sensory performance.
Brief History
1988
Nu-Mega Lipids JV with Heinz and access to a novel supply of marine omega-3 oil.
1996
A world first introduction of LCPUFA (Long Chain Poly Unsaturated Fatty Acids) via capsules into infant formula.
1998
Began world’s first supply of microencapsulated LCPUFA (Long Chain Poly Unsaturated Fatty Acids) into infant formula.
2002
First in the world to market next generation 50% oil loaded technology.
2003
Developed high temperature stable delivery technology, partnering with a well-known Australian brand, which went on to be one of the most successful functional food launches in the world (adjusted for PPP and population).
2003-2007
Nu-Mega Ingredients formed via JV between Clover Corporation and Food Spectrum.
2007
Nu-Mega Ingredients became 100% subsidiary of Clover Corporation, a consistently profitable, strong, technical, manufacturing and sales organization.
2013
Global leader in delivery of stable micronutrients to the global infant nutrition and special medical market with a reputation for excellence in everything it does.
Beyond 2018, we’re committed to the delivery of the next generation in infant nutrition with a focus on delivering innovative products in the following areas:
Novel fatty acids with health benefits in infant nutrition
Microencapsulation technologies for Infant nutrition
Preterm infant and medical nutrition
Nu-Mega products have been a trusted brand for high quality DHA (Docosahexaenoic Acid) oil and micro encapsulated omega-3 and omega-6 oils since 2001. These products are designed to deliver health outcomes in a stable and bioavailable format.
The three principle health benefits attributed to consumption of the long chain Omega-3 PUFAs (Polyunsaturated Fatty Acids), EPA (Eicosapentaenoic Acid) and DHA (Docosahexaenoic Acid) are:
Brain Development and cognitive functioning.
Developmental and maintenance role in visual acuity.
Cardiovascular health and disease prevention/recovery.
World Class Technology
Clover's superior microencapsulation technology enables nutritional oils, such as tuna, fish, algal and fungal oils, to be added to infant formula, foods and beverages. Developed through extensive research and development, our proprietary technologies protect those sensitive oils from oxidation, allowing them to be incorporated into a range of applications. All of our products reach the highest standards of purity, stability and performance, allowing you to maximise and deliver nutrition whilst masking unpleasant taste and odour.
Company Fundamentals
Clover Corporation Limited (Clover) has reported a Net Profit after Tax of $3.2 million for the HALF YEAR ended 31 January 2018 (2017: $1.0 million) an increase of 209%. Sales revenue increased 60% to $31.0 million (2017: $19.4 million). The company has improved its gross margin rate for the period, and has broadened its product and customer base, which have delivered solid revenue growth and improved profitability.
Clover has benefited from adding new customers who add volume, profitability and scope for further growth. Growing the customer base has been a long term priority of the business, and the combined efforts of the Commercial and Research divisions has delivered the service necessary to take customers through the long product development and shelf life trial process to prove Clover’s products and cement new relationships & revenue.
Clover’s traditional customers have experienced significant growth in production driven by demand in their home countries and in China. The new trading terms the company has negotiated have maintained its customer base.
Demand from customers selling into China has been strong through the last six months, demonstrating a continuation of the sales patterns seen in the second half of FY17. Clover’s customers have been focused on achieving Chinese CFDA accreditation, which effectively is a licence to sell product into China through the traditional “bricks & mortar” channels of supermarkets, mum & baby stores and pharmacies. No additional changes to the Chinese regulations has created stability and confidence for the manufacturers, with the “grey market” and traditional market showing significant growth. While this stability lasts, Chinese demand is expected to be maintained at current levels. For Clover, this is reflected in increased sales in the Australia and New Zealand region, where much of the product going into China is manufactured.
The Company’s balance sheet remains strong with cash at $6.7 million and net assets of $34.6 million (2017: $32.6 million). The inventory position reflects the strong demand, currently at $18.5 million (2017: $18.8 million).
The Company completed the purchase of its manufacturing site in Altona, Victoria and as at March 2018 has consolidated its Victoria operations onto one site.
OPERATIONAL SUMMERY
Clover continues to work with distributors and new customers across different territories and market segments to provide a pipeline of opportunities for future growth. A new highly concentrated docosahexaenoic acid (DHA) product released in late 2017 has been successfully incorporated into gummies in the USA, where the product is now being sold into the children’s and seniors’ markets.
The company has several other products on trial with customers in drink, sports bars and powder applications. The development of new products, which takes time from a market and product testing perspective, is an ongoing process and will continue, with additional opportunities being sought.
Clover has successfully participated in international exhibitions in the USA, Europe and Asia to develop its profile and provide exposure to new customers and markets.
The current demand conditions, stability of Chinese regulations, and growth of new customers is expected to continue in the near term, with the Company expecting demand patterns from customers to continue in the second half of the year, with third quarter orders being consistent with first half FY18 sales.
FUTURE GROWTH
Infant formula provides further growth
Increased Chinese demand and stability of regulations has driven increased volume across key markets
Key customers have achieved or are in the process of receiving their CFDA accreditation to market and to sell up to three brands in the Chinese market
All traditional customers have been maintained, with growth into new IF manufacturers and brands
Products for new segments-
Clover’s Hypoallergenic DHA product is now an ingredient across multiple goat IF brands
A new highly concentrated DHA product which delivers 60% oil loading in a powder form is being used in gummies targeting the child and seniors’ segments
Clover is continuing to invest in new product development with a pipeline of new products targeting additional segments and next generation delivery systems
Clover’s revenue growth has been enhanced by sales into the USA, Europe and Asia
Australia & New Zealand have delivered significant growth as the IF market increases volume to meet domestic and international demand
Clover continues to develop distribution partnerships targeting new segments and territories
Continued demand in the second half based on the existing activity levels and status of Chinese regulations
Expansion of production base to meet growth in demand
Development of new products targeting sports nutrition, children’s
and seniors’ health
Growth expected in Europe, USA and South America
Research & Development in collaboration with customers
Additional staff to service customers and deliver on opportunities
Improve efficiencies and reduce operating costs
Add value through strategic acquisition and/or partnership
Ps this was done on my phone which was painful as
Expand
(20min delay)
